Out of the Dark, Into the Light: Illuminating Modern Strategies for the Detection and Treatment of Bipolar Depression (Credit Expired)
Overview
Up to 80% of patients with bipolar disorder (BD) initially present with depression. However, without experience of or insight into their mania, these patients are easily misdiagnosed with major depressive disorder (MDD) or other psychiatric conditions. Once an accurate diagnosis is obtained, ensuring appropriate treatment of BD depression is essential, but a variety of misconceptions and outdated strategies significantly complicate this process. To help navigate diagnostic and management strategies for BD depression, this program – originally delivered as a virtual Grand Rounds series – reviews the self-reported diagnostic and management approaches of five renowned psychiatry experts and the underlying data that support those decisions.
Target Audience
This activity is intended for psychiatrists, nurse practitioners, physician assistants, and other healthcare professionals involved in the diagnosis and long-term management of patients with bipolar disorder.
Learning Objectives
Upon completion of the educational activity, participants should be able to:
- Discuss preferred approaches to and indicators for BD depression as well as its differentiation from other psychiatric disorders (e.g., MDD) to diagnose these patients early and accurately
- Examine the role of antidepressants in BD and determine whether they may be used safely for certain patient presentations
- Evaluate the mechanisms of action, clinical profiles, and supporting phase 3 trial data for therapies with recent approvals for BD depression to effectively integrate these agents into clinical practice
Presenting Faculty
Other Grand Rounds Project Steering Committee Members
Clinical Professor, Psychiatry and
Behavioral Sciences
Valhalla, NY
Credit for this program has expired. The accreditation information below is based on the activity release date.
This activity is jointly provided by Medical Education Resources (MER) and Efficient LLC.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Efficient LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Designation Statement
Disclosure of Relevant Financial Relationships
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in an accredited continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality accredited continuing education activities that promote improvements or quality in health care and not the business interest of an ineligible company.
Staff Disclosures
Faculty Disclosures
Craig Chepke, MD, DFAPA:
- Contracted Research: Acadia, Axsome, Biohaven, Harmony, Neurocrine, Teva
- Consulting Fees: AbbVie, Acadia, Alkermes, Axsome, BioXcel, Corium, Eisai, Genomind, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, MedinCell, Neurocrine, Noven, Otsuka, Takeda, Teva; Advisory Board (spouse): Otsuka
- Speakers’ Bureau: AbbVie, Acadia, Alkermes, Axsome, BioXcel, Corium, Eisai, Genomind, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Lundbeck, Merck, Neurocrine, Noven, Otsuka, Sunovion, Takeda, Teva
Leslie Citrome, MD, MPH:
- Contracted Research: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Eisai, Enteris BioPharma, HLS Therapeutics, Impel, Intra-Cellular, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Merck, Neurocrine, Novartis, Noven, Otsuka, Ovid, Relmada, Reviva, Sage, Sunovion, Teva, University of Arizona
- Consulting Fees: AbbVie/Allergan, Acadia, Alkermes, Angelini, Eisai, Intra-Cellular, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Takeda, and Teva,
Andrew J. Cutler, MD:
- Consulting Fees: AbbVie/Allergan, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Luye Pharma, Neumora/BlackThorn, Neurocrine, Noven, Otsuka, Relmada, Reviva Pharmaceuticals, Sage Therapeutics, Sunovion, Supernus, Takeda, Teva, Tris Pharma, VistaGen
- Speakers’ Bureau: AbbVie/Allergan, Acadia, Alfasigma, Alkermes, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Pharma
- Employee & Board Member: Neuroscience Education Institute
Joseph F. Goldberg, MD:
- Consulting Fees: BioXcel, Jazz Pharmaceuticals, Lundbeck, Otsuka, Sage, Sunovion, Supernus
- Speakers’ Bureau: AbbVie, Alkermes, Axsome, Intra-Cellular, Sunovion
- Royalty: American Psychiatric Publishing; Cambridge Univ. Press
Carmen Kosicek, MSN, APNP, PMHNP-BC:
- Consulting Fees: AbbVie, Boehringer Ingelheim, Corium, Eisai, Intra-Cellular, Teva
- Speakers Bureau: AbbVie/Allergan, Alkermes, Intra-Cellular, Teva, US World Meds
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Efficient LLC, and/or Intra-Cellular Therapies. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
Commercial Support
This activity is supported by an educational grant from Intra-Cellular Therapies.
Method of Participation
There are no fees for participating in and receiving credit for this activity. During the period November 15, 2023 through November 15, 2024, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form.
A statement of credit will be issued only upon receipt of a completed activity evaluation form.
Media
Internet